Board Change • May 20
No independent directors There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. No independent directors (7 non-independent directors). Director Mikael Kubista was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Ankündigung • Apr 02
Devyser AB completed the acquisition of CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO). Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million on February 11, 2026. The consideration consists of common equity of Devyser AB having a value of SEK 12.2 million to be issued for common equity of CyberGene AB. As part of consideration, SEK 12.2 million is paid towards common equity of CyberGene AB. The acquisition is fully financed through a directed issue of new shares in Devyser to the seller, to be paid by way of set-off against the seller’s claim on payment of the purchase price. Based on the authorization granted by the Annual General Meeting on 14 May 2025, the Board of Directors intends, subject to receipt of the necessary clearance from the Inspectorate of Strategic Products, to resolve upon an issue of new shares in Devyser. Level Bio AB (publ), as the seller of Cybergene, will be entitled to subscribe for the new shares.
The transaction is subject to approval by regulatory board / committee. The expected completion of the transaction is April 1, 2026.
The acquisition strengthens Devyser’s customer offering within the aneuploidy segment and is expected to have a positive impact on Devyser’s gross profit and gross margin.
Devyser AB completed the acquisition of CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) on April 1, 2026. The acquisition was conditional upon the receipt of all necessary clearances, approvals, decisions and other actions from the Inspectorate of Strategic Products under the Swedish Screening of Foreign Direct Investments Act. This closing condition has been fulfilled on April 1, 2026. The acquisition is consolidated from and including April 1, 2026 and is expected to have a positive impact on Devyser’s gross profit as well as EBIT. Ankündigung • Feb 12
Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million. Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million on February 11, 2026. The consideration consists of common equity of Devyser AB having a value of SEK 12.2 million to be issued for common equity of CyberGene AB. As part of consideration, SEK 12.2 million is paid towards common equity of CyberGene AB.
The transaction is subject to approval by regulatory board / committee. The expected completion of the transaction is April 1, 2026.
The acquisition strengthens Devyser’s customer offering within the aneuploidy segment and is expected to have a positive impact on Devyser’s gross profit and gross margin. The acquisition is fully financed through a directed issue of new shares in Devyser to the seller, to be paid by way of set-off against the seller’s claim on payment of the purchase price. Based on the authorization granted by the Annual General Meeting on 14 May 2025, the Board of Directors intends, subject to receipt of the necessary clearance from the Inspectorate of Strategic Products, to resolve upon an issue of new shares in Devyser. Level Bio AB (publ), as the seller of Cybergene, will be entitled to subscribe for the new shares. Reported Earnings • Apr 26
First quarter 2024 earnings released First quarter 2024 results: Revenue: kr5.67m (down 33% from 1Q 2023). Net loss: kr2.46m (loss widened 343% from 1Q 2023). Ankündigung • Mar 27
AlphaHelix Molecular Diagnostics AB (publ) to Report Q1, 2024 Results on Apr 25, 2024 AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q1, 2024 results on Apr 25, 2024 Ankündigung • Mar 20
AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024 AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024. Reported Earnings • Feb 25
Full year 2023 earnings released: kr0.15 loss per share (vs kr0.035 loss in FY 2022) Full year 2023 results: kr0.15 loss per share (further deteriorated from kr0.035 loss in FY 2022). Revenue: kr26.6m (down 23% from FY 2022). Net loss: kr9.48m (loss widened 326% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance. Ankündigung • Jan 24
AlphaHelix Molecular Diagnostics AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2024 AlphaHelix Molecular Diagnostics AB (publ) announced that they will report fiscal year 2023 results on Feb 22, 2024 New Risk • Oct 29
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr4.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr4.9m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (kr43.6m market cap, or US$3.91m). Minor Risk Revenue is less than US$5m (kr30m revenue, or US$2.7m). Ankündigung • Sep 27
AlphaHelix Molecular Diagnostics AB (publ) to Report Q3, 2023 Results on Oct 26, 2023 AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q3, 2023 results on Oct 26, 2023 Reported Earnings • Aug 28
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: kr5.39m (down 6.3% from 2Q 2022). Net loss: kr2.36m (loss narrowed 2.4% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 28% per year, which means it has not declined as severely as earnings. Ankündigung • Jul 26
AlphaHelix Molecular Diagnostics AB (publ) to Report Q2, 2023 Results on Aug 24, 2023 AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q2, 2023 results on Aug 24, 2023 Ankündigung • May 31
AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023 AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023. Reported Earnings • Apr 20
First quarter 2023 earnings released First quarter 2023 results: Revenue: kr8.48m (down 35% from 1Q 2022). Net loss: kr554.0k (down 139% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings. Reported Earnings • Feb 24
Full year 2022 earnings released: kr0.035 loss per share (vs kr0.087 profit in FY 2021) Full year 2022 results: kr0.035 loss per share (down from kr0.087 profit in FY 2021). Revenue: kr34.7m (down 21% from FY 2021). Net loss: kr2.22m (down 143% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 4% per year. Ankündigung • Jan 18
AlphaHelix Molecular Diagnostics AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023 AlphaHelix Molecular Diagnostics AB (publ) announced that they will report fiscal year 2022 results on Feb 16, 2023 Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Joakim Grånemo was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 30
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: kr5.63m (down 16% from 3Q 2021). Net loss: kr1.19m (loss widened kr1.09m from 3Q 2021). Valuation Update With 7 Day Price Move • Jul 27
Investor sentiment improved over the past week After last week's 19% share price gain to kr1.13, the stock trades at a trailing P/E ratio of 14.4x. Average trailing P/E is 43x in the Life Sciences industry in Sweden. Total returns to shareholders of 82% over the past three years. Reported Earnings • Apr 27
First quarter 2022 earnings released: EPS: kr0.022 (vs kr0.031 in 1Q 2021) First quarter 2022 results: EPS: kr0.022 (down from kr0.031 in 1Q 2021). Revenue: kr13.1m (up 39% from 1Q 2021). Net income: kr1.42m (down 12% from 1Q 2021). Profit margin: 11% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Neven Zoric was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 22
First quarter 2022 earnings released First quarter 2022 results: Revenue: kr13.2m (up 40% from 1Q 2021). Net income: kr1.42m (down 12% from 1Q 2021). Profit margin: 11% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Mar 23
Investor sentiment improved over the past week After last week's 17% share price gain to kr1.85, the stock trades at a trailing P/E ratio of 22.8x. Average trailing P/E is 56x in the Life Sciences industry in Sweden. Total returns to shareholders of 160% over the past three years. Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment deteriorated over the past week After last week's 19% share price decline to kr1.78, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 43x in the Life Sciences industry in Sweden. Total returns to shareholders of 122% over the past three years. Reported Earnings • Feb 18
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: kr0.081 (up from kr0.029 in FY 2020). Revenue: kr44.7m (up 90% from FY 2020). Net income: kr5.16m (up 241% from FY 2020). Profit margin: 12% (up from 6.4% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jan 24
Investor sentiment deteriorated over the past week After last week's 26% share price decline to kr1.96, the stock trades at a trailing P/E ratio of 25.9x. Average trailing P/E is 45x in the Life Sciences industry in Sweden. Total returns to shareholders of 141% over the past three years. Valuation Update With 7 Day Price Move • Jan 04
Investor sentiment improved over the past week After last week's 15% share price gain to kr2.88, the stock trades at a trailing P/E ratio of 38.1x. Average trailing P/E is 60x in the Life Sciences industry in Sweden. Total returns to shareholders of 224% over the past three years. Reported Earnings • Nov 01
Third quarter 2021 earnings released The company reported a mediocre third quarter result with weaker earnings and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: kr6.96m (up 42% from 3Q 2020). Net loss: kr107.0k (down 168% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 127% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Sep 14
Investor sentiment improved over the past week After last week's 25% share price gain to kr3.24, the stock trades at a trailing P/E ratio of 37.2x. Average trailing P/E is 50x in the Life Sciences industry in Sweden. Total returns to shareholders of 220% over the past three years. Valuation Update With 7 Day Price Move • Aug 30
Investor sentiment improved over the past week After last week's 16% share price gain to kr2.69, the stock trades at a trailing P/E ratio of 30.9x. Average trailing P/E is 50x in the Life Sciences industry in Sweden. Total returns to shareholders of 180% over the past three years. Reported Earnings • Aug 18
Second quarter 2021 earnings released: EPS kr0.056 (vs kr0.014 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr15.8m (up 153% from 2Q 2020). Net income: kr3.54m (up 363% from 2Q 2020). Profit margin: 22% (up from 12% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 117% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Aug 04
Investor sentiment improved over the past week After last week's 26% share price gain to kr2.23, the stock trades at a trailing P/E ratio of 51.4x. Average trailing P/E is 48x in the Life Sciences industry in Sweden. Total returns to shareholders of 133% over the past three years. Valuation Update With 7 Day Price Move • Jul 15
Investor sentiment improved over the past week After last week's 17% share price gain to kr1.89, the stock trades at a trailing P/E ratio of 43.6x. Average trailing P/E is 47x in the Life Sciences industry in Sweden. Total returns to shareholders of 81% over the past three years. Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment improved over the past week After last week's 19% share price gain to kr1.82, the stock trades at a trailing P/E ratio of 42x. Average trailing P/E is 45x in the Life Sciences industry in Sweden. Total returns to shareholders of 102% over the past three years. Valuation Update With 7 Day Price Move • May 26
Investor sentiment improved over the past week After last week's 21% share price gain to kr1.67, the stock trades at a trailing P/E ratio of 38.5x. Average trailing P/E is 41x in the Life Sciences industry in Sweden. Total returns to shareholders of 83% over the past three years. Reported Earnings • Apr 25
First quarter 2021 earnings released The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr9.46m (up 50% from 1Q 2020). Net income: kr1.61m (up 93% from 1Q 2020). Profit margin: 17% (up from 13% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Mar 09
Investor sentiment deteriorated over the past week After last week's 18% share price decline to kr1.40, the stock is trading at a trailing P/E ratio of 48.8x, down from the previous P/E ratio of 59.2x. This compares to an average P/E of 49x in the Life Sciences industry in Sweden. Total returns to shareholders over the past three years are 46%. Is New 90 Day High Low • Feb 09
New 90-day high: kr1.49 The company is up 52% from its price of kr0.98 on 10 November 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 27% over the same period. Is New 90 Day High Low • Jan 21
New 90-day high: kr1.44 The company is up 13% from its price of kr1.27 on 23 October 2020. The Swedish market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 4.0% over the same period. Valuation Update With 7 Day Price Move • Jan 20
Investor sentiment improved over the past week After last week's 21% share price gain to kr1.29, the stock is trading at a trailing P/E ratio of 57.3x, up from the previous P/E ratio of 47.6x. This compares to an average P/E of 52x in the Life Sciences industry in Sweden. Total returns to shareholders over the past three years are 27%. Valuation Update With 7 Day Price Move • Dec 29
Investor sentiment improved over the past week After last week's 36% share price gain to kr1.31, the stock is trading at a trailing P/E ratio of 39.4x, up from the previous P/E ratio of 28.8x. This compares to an average P/E of 46x in the Life Sciences industry in Sweden. Total returns to shareholders over the past three years are 19%. Valuation Update With 7 Day Price Move • Dec 22
Investor sentiment improved over the past week After last week's 17% share price gain to kr1.05, the stock is trading at a trailing P/E ratio of 31.5x, up from the previous P/E ratio of 26.9x. This compares to an average P/E of 44x in the Life Sciences industry in Sweden. Total return to shareholders over the past three years is a loss of 12%. Is New 90 Day High Low • Dec 01
New 90-day low: kr0.82 The company is down 37% from its price of kr1.30 on 02 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 4.0% over the same period. Valuation Update With 7 Day Price Move • Nov 03
Market pulls back on stock over the past week After last week's 20% share price decline to kr1.09, the stock is trading at a trailing P/E ratio of 63x, down from the previous P/E ratio of 78.5x. This compares to an average P/E of 56x in the Life Sciences industry in Sweden. Total return to shareholders over the past three years is a loss of 11%. Is New 90 Day High Low • Nov 03
New 90-day low: kr1.09 The company is down 26% from its price of kr1.48 on 05 August 2020. The Swedish market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 6.0% over the same period. Valuation Update With 7 Day Price Move • Oct 26
Market bids up stock over the past week After last week's 18% share price gain to kr1.38, the stock is trading at a trailing P/E ratio of 79.7x, up from the previous P/E ratio of 67.6x. This compares to an average P/E of 58x in the Life Sciences industry in Sweden. Total return to shareholders over the past three years is a loss of 8.6%. Is New 90 Day High Low • Oct 13
New 90-day low: kr1.20 The company is down 26% from its price of kr1.62 on 14 July 2020. The Swedish market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 25% over the same period. Ankündigung • Jul 30
Xanadu Technologies AB, Tataa Biocenter AB and Active Healthtech Nordic AB acquired a 13.17% stake in AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) from Labkompaniet AB. Xanadu Technologies AB, Tataa Biocenter AB and Active Healthtech Nordic AB acquired a 13.17% stake in AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) from Labkompaniet AB on May 6, 2020. Under the terms, 7 million shares were sold by Labkompaniet. Labkompaniet decreased its stake from 52.68% to 39.51%. Active Healthtech's will own 6.58%.
Xanadu Technologies AB, Tataa Biocenter AB and Active Healthtech Nordic AB completed the acquisition of a 13.17% stake in AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) from Labkompaniet AB on May 6, 2020.